激肽原酶联合厄贝沙坦治疗糖尿病肾病的疗效

Curative effect of irbesartan combined with kallidinogenase on early stage diabetic nephropathy

目的观察厄贝沙坦与胰激肽原酶联合治疗早期糖尿病肾病的疗效。方法将80例早期糖尿病肾病患者随机分为治疗组（厄贝沙坦＋胰激肽原酶）和对照组（胰激肽原酶）各40例。比较两组治疗前、后尿白蛋白排泄率、血尿素氮、血肌酐、血清白蛋白的变化。结果治疗12周后，两组尿白蛋白排泄率、血尿素氮、血肌酐均下降，血清白蛋白升高，治疗组治疗后差异更为显著。结论厄贝沙坦联合胰激肽原酶联合治疗早期糖尿病肾病较单药胰激肽原酶疗效更有效。

Objective To observe the curative effect of irbesartan combined with kallidinogenase on early stage diabetic nephropathy. Methods Eighty patients with DN were divived into two groups and treated by irbesartan combined with kallidinogenase and kallidinogenase alone respective-ly. The UREA, BUN, SCr, serum albumin （ALB） of the two groups before and after treatment were compare. Results The ALB levels of the two groups 12 weeks after treatment were increased, while other indexes decreased. However, the differences of above-mentioned indexes before and after treatment in the patients treated by irbesartan combined with kallidinogenase were more remarkable. Conclusions Compared with kallidinogenase alone, irbesartan combined with kallidinogenase has more ideal curative effect on early stage diabetic nephropathy.